Skip to main content

Table 1 Clinicopathologic factors of BC patients

From: Monitoring the responsiveness of T and antigen presenting cell compartments in breast cancer patients is useful to predict clinical tumor response to neoadjuvant chemotherapy

Patients’ clinical characteristics n
Age (years) mean 55.6
 <50 6
 >50 11
TNM (stage)
 1 1
 2 10
 3 6
Clinical stage
 IIA 2
 IIB 8
 IIIA 6
 IIIB 1
Clinical Lymph Node Classification
 cN0 3
 cN1 10
 cN2 4
 cN3 0
Systemic metastases
 No 17
 Yes 0
Residual Cancer Burden (RCB)*
 RCB-III 0
 RCB-II 11
 RCB-I 2
 pCR 4
Estrogen receptor (ER)
 Positive (>10%) 13
 Negative (<10%) 4
Progesterone receptor (PR)
 Positive (>10%) 10
 Negative (<10%) 7
Ki-67
 Positive (>14%) 4
 Negative (<14%) 13
Her2/neu
 Positive 5
 Negative 12
Scarff-Bloom-Richardson (SBR) grade
 I 0
 II 10
 III 7
Breast Cancer sub-types**
 Luminal A 3
 Luminal B 10
 Triple negative 3
 Her2/neu overexpressing 1
  1. *Classification based on MD Anderson Center RCB calculator
  2. **Luminal A: ER+ and/or PR+, HER-2− and Ki67 low. Luminal B: ER+ and/or PR+, HER-2− and/or HER-2+ and Ki67 high. Triple negative: ER− and PR− and HER-2−. Her2/neu overexpressing: ER- and Her2/neu+